Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a ...

AstraZeneca Plc (NASDAQ:AZN) on Monday released topline data from the DESTINY-Breast09 Phase 3 trial of Enhertu (5.4mg/kg) either alone or in combination with pertuzumab versus standard of care THP (a ...

This year's honorees span a wide range of categories, including innovators like hip hop legend Snoop Dogg, and actor Hiroyuki Sanada, from the FX series "Shōgun" on Hulu. Also recognized were ABC ...

4. Daiichi Sankyo, AstraZeneca's highly touted ADC Datroway off to 'smooth market launch' Daiichi Sankyo CEO Hiroyuki Okuzawa described the initial launch of AstraZeneca-partnered Datroway as ...

It was an indication of a “smooth market launch,” Daiichi CEO Hiroyuki Okuzawa said on a conference call late last week. Datroway has been approved for unresectable or metastatic, hormone ...

Hiroyuki Okuzawa, CEO of Japanese pharmaceutical giant Daiichi Sankyo, talks about the company's revenue driver in its latest report, and the lack of visibility from the impact of potential U.S ...

Shōgun's Hiroyuki Sanada accepts the Best Actor in a Drama Series award at the Critics Choice Awards Kevin Winter/Getty Images for Critics Choice Association Though Toranaga does not control the ...

Daiichi Sankyo promoted Hiroyuki Okuzawa as CEO, succeeding Sunao Manabe, DVM, PhD on April 1, 2025. Astellas’ chief commercial officer Claus Zieler is set to take up the new role of chief commercial ...

Daiichi Sankyo announced that Hiroyuki Okuzawa will serve as its new CEO starting on April 1, 2025. 1 The previous CEO, Sunao Manabe, DVM, PhD, will continue to serve as representative director and ...

Tokyo: Daiichi Sankyo Company, Ltd has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1, 2025. Dr. Manabe will transition from ...

Hiroyuki Okuzawa, current COO and incoming CEO of Daiichi Sankyo, talks about the pharmaceutical company's product pipeline, including its cancer treatments, and its global partnerships with ...

Daiichi Sankyo Company, , an innovative global healthcare company, has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as chief executive officer (CEO), effective April 1, 2025. Dr ...